Therapy News and Research

RSS

Fresenius Medical Care to acquire Euromedic's dialysis service business

Fresenius Medical Care AG & Co. KGaA, the world's largest provider of dialysis products and services, today announced the signing of a purchase agreement to acquire International Dialysis Centers ("IDC"), Euromedic International's ("Euromedic") dialysis service business.

4 Jan 2011

Encouraging results from exon skipping gene-based therapy study for DMD

Scientists at Royal Holloway, University of London have reported encouraging results in a new gene-based therapy for Duchenne Muscular dystrophy (DMD) which at present has no known cure and affects one in 3,000 young boys.

4 Jan 2011

New options in fertility preservation for oncology patients

Many young people who've just learned that they have cancer also are told that the therapies that may save their lives could rob them of their ability ever to have children. Infertility caused by chemotherapy and radiation affects a sizable population: Of the 1.5 million people diagnosed with cancer in 2009, nearly 10 percent were still in their reproductive years.

4 Jan 2011

AHF to supply $1 million in free AIDS drugs to Florida's disenrolled and wait listed HIV/AIDS patients

As the State of Florida grapples with a budget shortfall that has crippled its AIDS Drug Assistance Program (ADAP) and forced the state to potentially disenroll 350 Florida patients already on ADAP as well as place nearly 2,400 low-income Floridians on waiting lists to access lifesaving medications, AIDS Healthcare Foundation (AHF) has proposed an innovative plan to help state health officials and displaced HIV/AIDS patients bridge the transition to private patient assistance programs run by the major pharmaceutical companies.

4 Jan 2011

The Scientist examines how nonprofit, for-profit pharma groups are working together to make drugs more affordable for developing countries

"With philanthropists funneling billions of dollars into biomedical research and traditional drug discovery efforts producing fewer and fewer therapies, the line between for-profit and nonprofit life science companies is beginning to blur as both sides of the divide look for new options," The Scientist magazine writes in an article that examines the rise in collaborations between nonprofit pharmaceutical companies and for-profit groups.

4 Jan 2011

Centre Partners completes sale of Kaz to Helen of Troy

Centre Partners Management LLC ("Centre Partners"), a leading middle market private equity firm with offices in New York and Los Angeles, today announced the completion of the sale of Kaz, Inc. ("Kaz" or the "Company") to Helen of Troy Limited. Kaz is an international leader in health care and home environment consumer solutions. The transaction is valued at $260 million subject to certain closing working capital and other adjustments.

3 Jan 2011

Repros receives IRB approval for Androxal Phase IIb study in secondary hypogonadism

Repros Therapeutics Inc. today reported it has received Institutional Review Board (IRB) approval to commence the Phase IIb study of Androxal® in men with secondary hypogonadism. The Company has submitted the protocol for FDA comment and plans to begin enrolling subjects in January. Depending on the rate of subject enrollment, Repros hopes to have the study completed before the end of 2011.

3 Jan 2011

EDAP reduces outstanding debt by $4.6 million

EDAP TMS SA, the global leader in therapeutic ultrasound, announced today that it entered into agreements with certain holders of its senior debentures and warrants to redeem part of EDAP's outstanding convertible debt and cancel some of its outstanding warrants. Pursuant to these agreements, the Company issued 1,441,743 ordinary shares in the form of American Depositary Shares in exchange for 4,558 senior debentures (equivalent to USD 4,558,000) and 986,965 warrants, reducing the current outstanding debt by USD 4.6 million to USD 10.5 million.

3 Jan 2011

U.S. Physical Therapy acquires majority interest in 14 clinic physical therapy group

U.S. Physical Therapy, Inc., a leading national operator of outpatient physical therapy clinics, has acquired a majority interest in a 14 clinic physical therapy group located in the Southeast.

3 Jan 2011

FDA grants orphan drug status for Senesco's SNS01-T in treatment of multiple myeloma

Senesco Technologies, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company's lead drug candidate SNS01-T for treatment of multiple myeloma.

3 Jan 2011

Celera seeks FDA premarketing approval for KIF6 Genotyping Assay

Celera Corporation today announced that it has submitted a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration (FDA) for its KIF6 Genotyping Assay, a new molecular In Vitro diagnostic (IVD) test designed to detect a marker for risk of coronary heart disease (CHD) independent of traditional risk factors and aid clinical evaluation when statin treatment is being considered.

3 Jan 2011

Teenage autistic boy allowed sex change procedure

A 16 year old autistic schoolboy has been granted approval to begin treatment for a sex change. He will have the provision to have his sperm frozen in case he decides he wants children. The decision came from Family Court judge Justice Linda Dessau on an emergency application from the boy’s parents so that he can begin therapy before his puberty fully sets in.

30 Dec 2010

Immunitor reports positive safety imm01 clinical trial against tuberculosis

Immune Network Ltd., advises that Immunitor has published data from the first half of the 120-patient imm01 clinical trial of its V5 immunomodulator product against tuberculosis, including difficult-to-treat forms of the disease.

30 Dec 2010

General anesthesia's similarities with and differences from sleep and coma

The use of general anesthesia is a routine part of surgical operations at hospitals and medical facilities around the world, but the precise biological mechanisms that underlie anesthetic drugs' effects on the brain and the body are only beginning to be understood. A review article in the December 30 New England Journal of Medicine brings together for the first time information from a range of disciplines, including neuroscience and sleep medicine, to lay the groundwork for more comprehensive investigations of processes underlying general anesthesia.

30 Dec 2010

Low levels of microbe-killing molecules improve survival rate of people with CGD

Investigators at the National Institutes of Health have observed that the survival rate of people with a rare immunodeficiency disease called chronic granulomatous disease is greatly improved when even very low levels of microbe-killing molecules are present.

30 Dec 2010

Researchers to identify gene variants that cause ischemic stroke

Researchers from the University of Maryland School of Medicine are coordinating an international team of scientists working to identify genes or gene variants that may make a person more likely to have a particular type of stroke called an ischemic stroke.

30 Dec 2010

FDA approves Impax's ANDA for generic Doryx 75 and 100mg tablets

Impax Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company's Abbreviated New Drug Application for the generic version of Doryx® (doxycyline hyclate delayed-release) 75 and 100mg tablets. The Company is preparing for product launch through Global Pharmaceuticals, Impax's generic division.

29 Dec 2010

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

Centocor Ortho Biotech Inc. announced today that it has filed a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) requesting the approval of REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy.

29 Dec 2010

CFTR protein regulates inflammation and cell death in emphysema, chronic lung diseases

A team of Johns Hopkins Children's Center researchers has discovered that a protein involved in cystic fibrosis also regulates inflammation and cell death in emphysema and may be responsible for other chronic lung diseases.

29 Dec 2010

CEL-SCI initiates Multikine Phase III trail for head and neck cancer

CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy. CEL-SCI has now completed all of the manufacturing and regulatory requirements to begin enrollment of the study.

29 Dec 2010

Therapy News and Research

Fresenius Medical Care to acquire Euromedic's dialysis service business

Encouraging results from exon skipping gene-based therapy study for DMD

New options in fertility preservation for oncology patients

AHF to supply $1 million in free AIDS drugs to Florida's disenrolled and wait listed HIV/AIDS patients

The Scientist examines how nonprofit, for-profit pharma groups are working together to make drugs more affordable for developing countries

Centre Partners completes sale of Kaz to Helen of Troy

Repros receives IRB approval for Androxal Phase IIb study in secondary hypogonadism

EDAP reduces outstanding debt by $4.6 million

U.S. Physical Therapy acquires majority interest in 14 clinic physical therapy group

FDA grants orphan drug status for Senesco's SNS01-T in treatment of multiple myeloma

Celera seeks FDA premarketing approval for KIF6 Genotyping Assay

Teenage autistic boy allowed sex change procedure

Immunitor reports positive safety imm01 clinical trial against tuberculosis

General anesthesia's similarities with and differences from sleep and coma

Low levels of microbe-killing molecules improve survival rate of people with CGD

Researchers to identify gene variants that cause ischemic stroke

FDA approves Impax's ANDA for generic Doryx 75 and 100mg tablets

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

CFTR protein regulates inflammation and cell death in emphysema, chronic lung diseases

CEL-SCI initiates Multikine Phase III trail for head and neck cancer

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News